TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tharimmune ( (THAR) ) has issued an update.
Tharimmune, Inc. faced a challenge when it received a notice from Nasdaq on April 1, 2025, indicating that its stockholders’ equity was below the required $2,500,000 for continued listing on the Nasdaq Capital Market. To address this, the company executed a series of financial transactions, including a registered direct offering and a private placement, raising a total of approximately $7.05 million by August 27, 2025. These actions successfully increased Tharimmune’s stockholders’ equity above the Nasdaq requirement, thereby securing its listing status.
The most recent analyst rating on (THAR) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Tharimmune stock, see the THAR Stock Forecast page.
More about Tharimmune
Average Trading Volume: 10,023,049
Technical Sentiment Signal: Buy
Current Market Cap: $23.53M
See more insights into THAR stock on TipRanks’ Stock Analysis page.